Author: Mahrukh Rehan

Gold Royalty Corp. (GROY) stock experienced an increase of 14.56% in the premarket. However, the last trading session closed at $4.72 with a decrease of 0.24%.

What’s happening?

GROY didn’t publish any latest press release in today’s date. Yet there is the recent news regarding GROY that is as follows:

GROY Secures Up to US$25 Million Revolving Credit Facility

GROY announces on 3 September 2021 that it has signed a commitment letter with the Bank of Montreal. That letter is for a fully underwritten US$10 million revolving credit facility. The Facility will be used for general company objectives, as well as acquisitions and investments.

The Facility will shut on September 30, 2021, with a maturity date of December 31, 2022. The Facility is subject to final paperwork and advance conditions.

GROY Completes Strategic Investment in Prospector Royalty Corp.

On 31 August 2021, GROY Completes Strategic Investment in Prospector Royalty Corp. GROY announces a strategic collaboration with Prospector Royalty Corp. It also merges with Timothy Young’s appointment to its Advisory Board.

Furthermore, GRC has invested C$2 million in PRC in exchange for a 12.5 percent stake. Timothy Young, Bill Rand, Zach Flood, Francis MacDonald, and Kenorland Minerals Ltd. are among the company’s founders. GRC has engaged in a royalty referral agreement. This will allow GRC to obtain certain royalties identified by PRC’s unique digitized royalty database.

Acquires Gold Prospect in Established Nevada Mining District

Firstly, GROY announced on 20 August 2021 that it has agreed to buy a 100 percent stake in the Bald Peak Project in Mineral County. Ely Gold Royalties Inc. was recently bought by Gold Royalty Corp., and Nevada Select is a completely owned subsidiary of Ely Gold Royalties Inc.

Secondly, MoThe lucrative Bodie-Aurora-Borealis area has produced over 3 million ounces of gold from open-pit mines. Bald Peak is a huge gold and silver epithermal system with many kilometers of promising terrain. In a well-defined 4-mile-long structural structure, gold and silver mineralization is linked with highly silicified rock. Surface outcropping has yielded rock samples with gold concentrations above 8 g/t.

Monarch Mining Corporation Announces the Closing of the $11.25 Million Transaction with GROY.

On 5^th August 2021, GROY stated the completion of the previously announced transaction with Gold Royalty Corp. According to this, Gold Royalty purchased the royalty interests from Monarch for $11.25 million in cash.

Lastly, a 2.5 percent net smelter return royalty on each of the Croinor Gold, McKenzie Break, and Swanson assets, of which half (1.25 percent) can be bought back by Monarch in the future for $2 million per site if certain criteria are satisfied.

Petróleo Brasileiro S.A. – Petrobras (PBR) stands at $9.75  in the premarket. However, the last trading session closed at $9.75 with a decrease of 7.58%.

PBR Announces Settlement of Cash Tender Offers

PBR reported the final findings and settlement of Petrobras Global Finance on 11 June 2021. The Offers were made in accordance with the terms outlined in the offer. However, the notice of assured delivery accompanied it together. PGF paid about US$2.45 billion in total to holders whose Notes were accepted for acquisition.

PBR Announces Offering of U.S. Dollar-Denominated Global Notes

PBR announces Offering of U.S. Dollar-Denominated Global Notes on 2^nd June 2021. The New Notes will constitute PGF’s unsecured liabilities. The net proceeds from the sale of the New Notes will be used to acquire Tender Notes. These are the ones that PGF accepts for purchase in the Tender Offers, with any leftover net proceeds.

According to PBR, they are not conditional on the tender of a certain quantity. A Tender Offer’s completion is not contingent on the completion of the other Tender Offers. Furthermore, each Tender Offer is distinct from the others, and PGF has the right to withdraw or amend any Tender Offer without affecting the other Tender Offers.

Monthly Production Increasing from the Caburé Natural Gas Project

PBR announced that Alvopetro Energy’s Caburé natural gas field now produces over 11 MMcf/d. This onshore natural gas field locates in the Brazilian state of Bahia, north of Salvador. In the Gomo Deep Basin, the firm is also constructing a natural gas project in the concession blocks directly north of the Caburé field. Moreover, management has a track record of successfully forming corporate alliances in order to bring its Caburé assets to commercial production.

Last but not the least, the government is now supporting natural gas market investments with the aim of decreasing gas costs. The government can do this by enhancing competition and opening the market to additional operators.

Aterian, Inc. (ATER) has experienced a decrease of 3.37% in the aftermarket. However, the last trading session concluded on $9.21 with a decrease of 29.35%.

What’s happening?

ATER has not declared any latest news or any press release. Yet there are some recent updates regarding ATER.

ATER launches Shareholder Perks Program

On 30 August 2021, ATER announced the introduction of the Shareholder Perks Program. The program offers Aterian stockholders who satisfy specific requirements different discounts on the company’s best-selling items.

Shareholders who join the Perks Program will receive weekly emails with attractive savings they can use across different platforms.

ATER published second quarter 2021 results

ATER announced second-quarter results 2021 on 9^th August 2021. In the second quarter of 2020, net sales increased by 14% to $68.2 million. The Gross margin increased to 48.0 percent in the second quarter of 2020

Compared to an operating loss of $(1.8) million in the second quarter of 2020, operating income increased to $4.5 million. This included a $23.3 million profit from the change in fair value of earn-out obligations.

Last but not the least, the contribution margin fell to 8.3 percent in Q2 2021, down from 16.8 percent in Q2 2020.

ATER announces investigation of Array Technologies

On 6^th August 2021, ATER announces the filing of a class-action lawsuit against ARRY. They state that ARRY made false and misleading statements because they failed to disclose the prices of certain commodities, such as steel.

The Complaint further claims that the Company’s Offering Materials made false and misleading representations. They did so by omitting that increases in commodity and freight prices had been negatively impacting the Company’s business and operations prior to the Offerings.

Conclusion

Investors have reacted badly to the release of financial data for the second quarter of 2021. When compared to the same period the previous year, the Aterian stock’s net loss has grown considerably. Before adding ATER stock to their portfolio, investors should conduct extensive research.

Cardiff Oncology, Inc. (CRDF) has seen an increase of 20.43% in the aftermarket after announcing new data from phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer. The last trading session concluded on $7.05 with a decrease of 4.6%.

CRDF announced new data from phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer

CRDF announced new data from phase 1b/2 Trial in KRAS-mutated Metastatic Colorectal Cancer on 8^th September 2021. 8 of 19 (42%) patients who were evaluable for illness response as of the data cut-off were treated per protocol at the recommended Phase 2 dosage (RP2D) of onvansertib 15 mg/m2 (PR). Historically, in a comparable patient group treated with standard of care chemotherapy, objective response rates (ORR) of 5-13 percent have been reported1-4.

Across all dosage levels, 12 of 32 (38%) patients evaluable for the response as of the data cutoff date had a PR. The median progression-free survival (mPFS) among all response-evaluable patients is 9.4 months, although it has yet to be attained in those treated according to protocol at the RP2D. In the past, a comparable patient cohort treated with standard of care chemotherapy was found to have a median PFS of 4.5-5.7 months1-4.

Participation in Upcoming Conferences

CRDF stated on September 7, 2021, that it is going to participate in the upcoming conferences. Cardiff Oncology’s chief executive officer, Mark Erlander, Ph.D., and chief financial officer, James Levine, will present and participate in virtual 1×1 investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference and the 2021 Cantor Virtual Global Healthcare Conference from September 13 – 15th 2021 and September 27 – 30th 2021 respectively.

CRDF published second quarter 2021 financial results

On 5^th August 2021, CRDF announced second-quarter 2021 financial results. Cardiff Oncology has about $140 million in cash, cash equivalents, and short-term investments as of June 30, 2021.

Total operational expenditures for the three months ended June 30, 2021, were about $7.0 million. The research and development costs grew by about $1.6 million to $4.1 million. The rise in R&D costs was largely due to the advancement of the onvansertib clinical and preclinical programs, as well as recruiting fees to fill the key post of chief medical officer.

For the three months ended June 30, 2021, selling, general, and administrative expenditures grew by about $1.1 million to $2.8 million.

In the second quarter of 2021, net cash spent in operating operations was about $4.3 million, which is similar to the $4.3 million used at the same time in 2020.

Globalstar, Inc. (GSAT) stock has experienced a gain of 4.09% in the aftermarket on September 8, 2021. However, the last trading session ended at $2.69 with an increase of 29.95%.

What’s happening?

There is no latest news on why are GSAT stock prices increasing. The Globalstar company did not issue any news or press releases too. Let’s dig into the recent news launched by the company in order to interpret the situation.

Second Quarter 2021 Financial Results released by GSAT

On 5^th August 2021, GSAT published second-quarter financial results 2021. The total revenue for the second quarter of 2021 was somewhat lower than the same period in 2020. Lower service revenue was compensated by higher revenue from subscriber equipment purchases.

The loss from operations in the second quarter of 2021 was $16.0 million, compared to $15.4 million in the second quarter of 2020. The rise in operating loss was largely attributable to $0.5 million in higher operational expenditures. A $0.8 million drop was reported in the value of inventory in the second quarter of 2021 due to outdated materials for discontinued goods.

The partnership of GSAT with FocusPoint International

On 1^st July 2021, it was announced that GSAT has established a collaboration with FocusPoint International Inc. to deliver crisis help services to Globalstar clients throughout the world through the Global Overwatch & RescueTM Plan.

Overwatch & Rescue is a FocusPoint International help package that includes significant travel medical and security advantages, as well as no-cost evacuations for customers who opt for the yearly plan. Overwatch & Rescue includes 24-hour multilingual crisis support, medical and dental referrals, and much more.

Customers who add the Overwatch & Rescue Plan to their Globalstar or SPOT account will have access to a team of highly experienced medical, security, and crisis response specialists to address incidents caused by dangerous summer and winter sports, natural disasters, pandemics such as COVID-19, riots, strikes, and other unplanned events that disrupt their travels and adventures.

SPOT Partners with Desert Vets Racing

On 19 May 2021, it was stated that SPOT LLC, a wholly-owned subsidiary of GSAT and a leader in satellite messaging and emergency notification technologies, has made a collaboration with Desert Vets Racing, an off-road racing organization founded by military veterans for veterans and active-duty personnel.

SPOT will supply the organization with goods and services to allow communication and driver safety when off-roading in places where there is no terrestrial access as part of the collaboration.

Oragenics, Inc. (OGEN) experienced an increase of 2.89% in the premarket without any specific reason. The last trading session closed at $0.6911 with a decrease of 4.01%.

Oragenics’ SARS-CoV-2 Spike Protein

On 30 August 2021, OGEN announced that when administered with several novel intramuscular (IM) and intranasal (IN) adjuvants, the stabilized pre-fusion spike protein trimer generates neutralizing antibodies in mice after immunization against SARS-CoV-2.

The expression platform, which was created with the help of Oragenics’ Canadian collaborator, will speed up the testing of hybrid SARS-CoV-2 antigen candidates, which will begin dosing at the end of this month in a hamster viral challenge trial.

OGEN Enters into Licensing Agreement

Oragenics has announced on 27 July 2021 that the company has reached an agreement with the National Research Council of Canada (NRC) to explore the fast development of next-generation vaccines against the SARS-CoV-2 virus and its variations. Oragenics now has a platform that can create cell lines for the high-yield synthesis of spike protein antigens for existing and upcoming variations of concern, thanks to NRC technology in conjunction with NIH components present in the Company’s Terra CoV-2 vaccine.

This technology should allow cell lines to be produced in six to eight weeks once the spike gene sequence is available, as opposed to six to nine months for typical cell line manufacturing. The NRC technologies will speed up the evaluation of SARS-CoV-2 antigen candidates in preclinical and clinical investigations, thanks to funding from the NRC’s Pandemic Response Challenge Program.

OGEN Announces Changes in Management and Board of Directors

On 3 May 2021, OGEN announces changes in management and board of directors. Dr. Alan Joslyn resigned as Chief Executive Officer, President, and Director of Oragenics, Inc. on May 2, 2021, to explore other opportunities.

Until a new CEO is appointed, the Company will be guided by the Board of Directors, with Dr. Frederick Telling moving from Chairman of the Board to the newly created role of Executive Chairman, starting immediately. To fill the position left by Dr. Joslyn’s departure, Mr. Sullivan, the Company’s current Chief Financial Officer, will serve as temporary principal executive officer.

OGEN Enters into Material Transfer Agreement

It was stated on 9 March 2021 that Biodextris Inc. has engaged in a material transfer agreement for the use of three intranasal mucosal adjuvants in the Terra CoV-2 vaccine against COVID-19, according to the company. Vaccination adjuvants are used to boost the immunogenicity of the vaccine. BDX100, BDX300, and BDX301 are proteosome-based adjuvants made up of proteins and lipopolysaccharides that have increased immune response, manufacturing efficiency, and the ability to administer vaccines intranasally.

The three intranasal adjuvants will be utilized in combination with Oragenics’ antigen vaccine candidate in the preclinical immunological assessment of Terra CoV-2 for the prevention of coronavirus illness induced by infection with the SARS-CoV-2 virus, according to the first agreement.

The findings from the tests using the novel intranasal vaccine candidate might be used to support an Investigational New Drug (“IND”) application to the US Food and Drug Administration (“FDA”) and a clinical trial application to Health Canada.

Kadmon Holdings, Inc. (KDMN) experienced a huge increase of 76.42% in the premarket on 8^th September 2021 because Sanofi is acquiring Kadmon in order to expand the transplant business. The last trading session concluded on $5.3 with an uprise of 1.34%.

Sanofi to Acquire KDMN

It is announced on 8^th September 2021 that Sanofi and Kadmon Holdings, Inc. have signed a formal merger agreement. Sanofi will immediately add RezurockTM (belumosudil) to its transplant portfolio as part of its goal to continue to expand its General Medicines core assets. Rezurock is a first-in-class treatment for chronic graft-versus-host disease (cGVHD) in adults and children 12 years and older who have failed at least two previous lines of systemic therapy.

KDMN Announces U.S. Availability of REZUROCK

KDMN announces on 19^th August 2021 that REZUROCKTM (belumosudil) 200 mg tablets are now commercially available for shipping to prescription patients in the United States. REZUROCK was authorized by the US Food and Drug Administration (FDA) on July 16, 2021, for the treatment of chronic graft-versus-host disease (cGVHD) in adults and children aged 12 and above who have failed at least two prior lines of systemic therapy.

KDMN reports second financial 2021 results

KDMN reported the second financial 2021 results on 5^th August 2021. Losses from operations were $32.0 million and $59.4 million for the three and six months ended June 30, 2021, respectively.

The $5.6 million and $11.2 million increases in operating expenses for the three and six months ended June 30, 2021, respectively, were primarily due to belumosudil commercial launch readiness activities, non-cash stock compensation expenses, and direct external research and development costs of developing preclinical product candidates from our immuno-oncology platform.

Cash, cash equivalents, and marketable debt securities totaled $270.5 million as of June 30, 2021, up from $123.9 million as of December 31, 2020. The Company anticipates that its present financial position will enough support its operations and planned expenditures through 2023.

REZUROCK Added to National Comprehensive Cancer Network

As stated by KDMN on August 4, 2021, that REZUROCKTM tablets have been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation (HCT) in the Pre-Transplant Recipient Evaluation and Management of Graft-Versus-Host Disease. REZUROCK is currently included as a recommended systemic agent for steroid-refractory chronic GVHD in the NCCN Guidelines in the United States, with a Category 2A designation.

DPW stock price inclined to $2.8 with an increase of 4.87% in the premarket. However, the last trading session concluded at $2.67 with an incline of 0.38%.

What’s happening?

No latest news on DPW stock has been observed for today. Yet there is some current news that will be covered in this post. Let’s dig deep into it.

DPW Regains Compliance with NYSE American Continued Listing Standards

On 17^th August 2021, DPW reported that AGH has achieved compliance with all continuing listing criteria set out in Section 704 of the NYSE American Company Guide, according to a letter from the NYSE American LLC.

AGH has resolved its continued listing deficiency by meeting the continued listing requirements, and the “BC” designation, which denotes noncompliance with the NYSE American’s listing standards.

DPW announces second-quarter financial results 2021

DPW announces second-quarter financial results 2021 on 16^th August 2021. Revenue was $75.4 million, 585 percent more than the previous six-month period’s; while the Company began cryptocurrency mining activities with about 1,000 miners, generating revenue of $421,000; and

In the previous six months, the company had a net loss of $7.9 million, resulting in a net income of $44.2 million.

Additional Investment in Alzamend announced by DPW

It was stated by DPW on 4^th August 2021 that Digital Power Lending, LLC (“DPL”), a wholly-owned subsidiary of Alzamend Neuro, Inc., a related party, and early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders,  which required additional investment in Alzamend Neuro, Inc.

The US Food and Drug Administration issued Alzamend a “study may proceed” letter on July 28, 2021, for a Phase 1a study under Alzamend’s Investigational New Drug application for AL001, a lithium-based ionic cocrystal oral therapy for patients with dementia-related to mild, moderate, and severe cognitive impairment associated with Alzheimer’s disease.

Based on the achievement of this milestone, Alzamend sold an additional 1,333,333 shares of its common stock to DPL for $2 million and issued warrants to DPL to acquire 666,667 shares of Alzamend common stock. The goal of this investment in Alzamend was to provide the company with a committed source of cash based on milestones to support Alzamend’s therapeutic treatments until Phase 1 clinical trials were completed.

Formation of Ault Global Real Estate Equities

On July 16, 2021, DPW announced the formation of Ault Global Real Estate Equities, Inc., a Nevada corporation, to invest in commercial real estate in the United States, with a focus on the middle-market category. To drive this approach, AGREE has named Christopher K. Wu as its Chief Executive Officer.

Conclusion

In comparison to the same period last year, the second-quarter performance of DPW stock is remarkable. In terms of sales and operations, the stock is improving. Lending and trade operations have experienced tremendous development. The DPW stock has a robust balance sheet. In a nutshell, long-term investors may find this stock to be an excellent investment.

Support.com, Inc. (SPRT) experiences an increase of 4.4% in the aftermarket on 7^th September 2021. However, the last trading session closed on $19.3 with a decrease of 12.07%.

What’s happening?

There is no latest news released by SPRT on today’s date. Yet there is some recent news that needs to be covered.

Vote “FOR” the Proposed Transaction with Greenidge Generation Holdings Inc.

On 1^st September 2021, Institutional Shareholder Services (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), two of the leading independent proxy advisory firms, have recommended that Support.com shareholders vote “FOR” the proposed transaction with Greenidge Generation Holdings Inc. (“Greenidge”) at Support.com’s upcoming special meeting on September 10, 2021. In agreement with the unanimous advice of the Support.com Board, both ISS and Glass Lewis suggest that shareholders vote “FOR” all proposals to be presented at the special meeting.

SPRT announces second-quarter financial results 2021

SPRT announced second-quarter financial results in 2021 on 13^th August 2021. Total revenue for the second quarter of 2021 was $8.5 million, which is $2.5 million less than the $11.0 million loss encountered in the second quarter of 2020.

In the second quarter of 2021, gross profit was $3.0 million and gross profit margin was 35 percent, less than 37 percent in the first quarter of 2021.

Also, the merger-related expenditures were in total $0.7 million in the second quarter of 2021 and $1.5 million in the first quarter of 2021, both of which were included in operating expenses.

Merger Transaction Process

Greenidge Generation Holdings Inc. has provided an update on the merger transaction process (“Greenidge”) on August 12, 2021.

As previously stated, Support.com and Greenidge agreed to an agreement on March 19, 2021, under which Support.com will be acquired by Greenidge in a merger transaction. On September 10, 2021, at 8:00 a.m., Support.com will convene a special meeting of its stockholders.

SPRT announces to expand Tech Support Capabilities

SPRT announced the introduction of HomesourcingSM Cloud, a new platform to enhance its technical support services on 4th August 2021. The HomesourcingSM Cloud platform is a secure, patented cloud-based platform that supports a worldwide workforce. ExpertToolkitSM, SecureHubSM, and ExpertCRMSM provide home-based specialists access to a set of technologies that allow them to handle even the most difficult issues.

These materials are part of Support.com’s white-labeled premium tech support subscription services for major companies, as well as direct to businesses and professional services firms, and consumers.

Macrogenics (MGNX) stock experiences a tremendous fall of 9.96% after the research concluded that breast cancer survival rates for the medication did not surpass normal treatment. However, the last trading session closed at $21.78 with a decrease of 3.2%.

MGNX Announces Final Overall Survival Results from SOPHIA Study

MGNX announced on 7^th September 2021 that according to Overall survival (OS) MARGENZA did not have any significant benefit over trastuzumab. The SOPHIA Phase 3 study’s final overall survival (OS) outcomes in adult patients with metastatic HER2-positive breast cancer.

The United States Food and Drug Administration (FDA) authorized MARGENZA in conjunction with chemotherapy in 2020 for adult patients with metastatic HER2-positive breast cancer who had undergone two or more previous anti-HER2 regimens.

The results of the SOPHIA trial, which compared MARGENZA with chemotherapy versus trastuzumab plus chemotherapy in patients with metastatic HER2-positive breast cancer, formed the foundation for its complete approval.

Participation in upcoming conferences

MGNX announced to participate in certain upcoming conferences on 2^nd September 2021. In September, the Company’s management will attend the following investment conferences:

The 16th Annual BioPharma Virtual Conference will be hosted by Citi. On Thursday, September 9, 2021, at 1:25 p.m. ET, MacroGenics’ President and Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a panel discussion titled Novel Antibodies and Protein Therapies in Oncology.

The 23rd Annual Global Investment Conference of H.C. Wainwright will take place from September 13-15, 2021. MacroGenics management will engage in a fireside chat, which will be accessible for on-demand watching. In addition, management will meet with employees one-on-one.

The Cantor Virtual Global Healthcare Conference will be held on 30^th September 2021. Management from MacroGenics will participate in a fireside talk on Thursday, September 30, 2021, at 12:40 p.m. ET.

MGNX announces 2^nd Quarter Financial results 2021

MGNX stated financial results of 2^nd quarter 2021 on 29 July 2021. Total revenue for the quarter ended June 30, 2021, was $30.8 million, largely from collaboration partnerships, with $3.2 million in net sales of MARGENZA.

This was largely attributable to a $14.4 million revenue recognition from Zai Lab linked to the recent June 2021 cooperation announcement, as well as a $5 million milestone recognition from Incyte Corporation.

However, MGNX faced a net loss of $39.9 million for the quarter ended June 30, 2021.